Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039558 | 0.96 | EPHX2 (0.61) | EPHX2OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL2908406 | 0.95 | EPHX2 (0.54) | EPHX2CYP2C9LMNAMAPK1NLRP1 | |
| SCHEMBL2903808 | 0.94 | EPHX2 (0.57) | EPHX2OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL2906992 | 0.92 | EPHX2 (0.55) | EPHX2OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL3028889 | 0.90 | EPHX2 (0.59) | EPHX2OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL2908128 | 0.90 | EPHX2 (0.58) | EPHX2OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL3033802 | 0.89 | EPHX2 (0.59) | EPHX2OPRM1OPRD1OPRK1CYP2C9 | |
| SCHEMBL2906220 | 0.88 | EPHX2 (0.72) | EPHX2OPRM1OPRD1OPRK1CYP2C9 | |
| SCHEMBL3035313 | 0.87 | EPHX2 (0.56) | EPHX2OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL13239292 | 0.86 | EPHX2 (0.67) | EPHX2OPRM1OPRD1OPRK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | claimed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, FAH | EPHX2 5/4885OPRM1 3908/4885OPRD1 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.